Table 3 Subgroup analyses for the effect of sarcopenia on PFS in patients with metastases

Regions

 < 0.001

Asia

1.98

1.18 to 3.31

83.6

8

Europe

1.25

0.91 to 1.73

66.9

7

Gender

 < 0.001

Female ≤ 50%

1.53

1.12 to 2.11

79.8

12

Female > 50%

1.61

1.11 to 2.33

21.4

4

Original cancer type

 < 0.001

Gastrointestinal

1.28

0.87 to 1.89

79.9

6

Urologic

1.57

1.02 to 2.41

7.3

5

Endocrine Gland

2.16

1.36 to 3.43

0

2

Breast

1.51

0.60 to 3.80

0

2

Quality assessment

 < 0.001

Low risk of bias

1.56

1.10 to 2.21

77.1

11

High risk of bias

1.59

0.96 to 2.62

79.2

5

Type of HR

 < 0.001

Univariate

0.84

0.70 to 0.98

50.9

6

Multivariate

1.01

0.81 to 1.22

57.8

10